Literature DB >> 11263760

Alzheimer's disease: current and future therapeutic perspectives.

S Gauthier1.   

Abstract

1. A better understanding of the pathophysiology of AD has been made possible through population-based epidemiological studies, human genetic and post-mortem studies, leading to a number of testable hypothesis towards delaying progression. 2. A number of disease milestones have been identified as therapeutic targets, such as conversion from MCI to diagnosable dementia. 3. Clinicians caring for patients with AD have currently available a number of symptomatic drugs, and will have in the future the ability to predict the risk for asymptomatic individuals to develop AD, and provide advice towards prevention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263760     DOI: 10.1016/s0278-5846(00)00149-4

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

Review 1.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

2.  Synthesis of Novel 3-Aryl-N-Methyl-1,2,5,6-Tetrahydropyridine Derivatives by Suzuki coupling: As Acetyl Cholinesterase Inhibitors.

Authors:  S B Benaka Prasad; Y C Sunil Kumar; C S Ananda Kumar; C T Sadashiva; K Vinaya; K S Rangappa
Journal:  Open Med Chem J       Date:  2007-09-05

3.  Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.

Authors:  Rajeshkumar U Koladiya; Amteshwar S Jaggi; Nirmal Singh; Bhupesh K Sharma
Journal:  BMC Pharmacol       Date:  2008-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.